<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39451540</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1467-3045</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Current issues in molecular biology</Title><ISOAbbreviation>Curr Issues Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Enhanced RBD-Specific Antibody Responses and SARS-CoV-2-Relevant T-Cell Activity in Healthcare Workers Following Booster Vaccination.</ArticleTitle><Pagination><StartPage>11124</StartPage><EndPage>11135</EndPage><MedlinePgn>11124-11135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/cimb46100660</ELocationID><Abstract><AbstractText>COVID-19 continues to impact healthcare workers (HCWs), making it crucial to investigate vaccine response rates. This study examined HCWs' humoral and cellular immunological responses to COVID-19 booster dosages. We enrolled thirty-four vaccinated HCWs. Twelve received a booster. Post-immunization, the participants' anti-COVID-19 IgG antibodies and IFN-γ secretion were assessed. The median second immunization response time was 406.5 days. Eighteen of twenty-two (81.8%) experienced breakthrough infections after the second vaccination, whereas ten out of twelve individuals who received booster doses had breakthrough infections (83.3%). Six of thirty-four HCWs (17.6%) had no breakthrough infections. Booster-injection recipients had a median antibody titer of 19,592 AU/mL, compared to 7513.55 AU/mL. HCWs with breakthrough infections exhibited a median antibody titer of 13,271.9 AU/mL, compared to 7770.65 AU/mL for those without infections. Breakthrough-infection and booster-injection groups had a slightly higher median T-cell response to antigens 1, 2, and 3. SARS-CoV-2 antibody titer and T-cell responsiveness were positively associated. HCWs sustain cellular and humoral immunity for over 10 months. Irrespective of the type of vaccine, booster injections enhance these immune responses. The results of our research are consistent with previous studies, and a multicenter investigation could validate the findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Souan</LastName><ForeName>Lina</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3310-8857</Identifier><AffiliationInfo><Affiliation>Department of Pathology &amp; Laboratory Medicine, King Hussein Cancer Center, Amman 11941, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Razeq</LastName><ForeName>Hikmat</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2833-6051</Identifier><AffiliationInfo><Affiliation>Department of Medicine, King Hussein Cancer Center, Amman 11941, Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Jordan, Amman 11942, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sughayer</LastName><ForeName>Maher A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-9185-9616</Identifier><AffiliationInfo><Affiliation>Department of Pathology &amp; Laboratory Medicine, King Hussein Cancer Center, Amman 11941, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21KHCC174F</GrantID><Agency>King Hussein Cancer Center</Agency><Country /></Grant><Grant><GrantID>Quantiferon kits were donated by QIAGEN Manchester Ltd.</GrantID><Agency>QIAGEN Manchester Ltd.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Curr Issues Mol Biol</MedlineTA><NlmUniqueID>100931761</NlmUniqueID><ISSNLinking>1467-3037</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgG levels</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">long immunity</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39451540</ArticleId><ArticleId IdType="pmc">PMC11506206</ArticleId><ArticleId IdType="doi">10.3390/cimb46100660</ArticleId><ArticleId IdType="pii">cimb46100660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharma A., Ahmad Farouk I., Lal S.K. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021;13:202. doi: 10.3390/v13020202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020202</ArticleId><ArticleId IdType="pmc">PMC7911532</ArticleId><ArticleId IdType="pubmed">33572857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kringos D., Carinci F., Barbazza E., Bos V., Gilmore K., Groene O., Gulácsi L., Ivankovic D., Jansen T., Johnsen S.P., et al. Managing COVID-19 within and across health systems: Why we need performance intelligence to coordinate a global response. Health Res. Policy Syst. 2020;18:80. doi: 10.1186/s12961-020-00593-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00593-x</ArticleId><ArticleId IdType="pmc">PMC7358993</ArticleId><ArticleId IdType="pubmed">32664985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehreth J. The global value of vaccination. Vaccine. 2003;21:596–600. doi: 10.1016/S0264-410X(02)00623-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00623-0</ArticleId><ArticleId IdType="pubmed">12531324</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbrook M., Gadoth A., Martin-Blais R., Gray A.N., Kashani S., Kazan C., Kane B., Tobin N.H., Ferbas K.G., Aldrovandi G.M., et al. Longitudinal Assessment of Coronavirus Disease 2019 Vaccine Acceptance and Uptake Among Frontline Medical Workers in Los Angeles, California. Clin. Infect Dis. 2022;74:1166–1173. doi: 10.1093/cid/ciab614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab614</ArticleId><ArticleId IdType="pubmed">34292319</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . The Impact of COVID-19 on Health and Care Workers: A Closer Look at Deaths. World Health Organization; Geneva, Switzerland: 2021.</Citation></Reference><Reference><Citation>Hughes K., Gogineni V., Lewis C., Deshpande A. Considerations for fair prioritization of COVID-19 vaccine and its mandate among healthcare personnel. Curr. Med. Res. Opin. 2021;37:907–909. doi: 10.1080/03007995.2021.1908245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2021.1908245</ArticleId><ArticleId IdType="pubmed">33760673</ArticleId></ArticleIdList></Reference><Reference><Citation>Smallwood N., Harrex W., Rees M., Willis K., Bennett C.M. COVID-19 infection and the broader impacts of the pandemic on healthcare workers. Respirology. 2022;27:411–426. doi: 10.1111/resp.14208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.14208</ArticleId><ArticleId IdType="pubmed">35048469</ArticleId></ArticleIdList></Reference><Reference><Citation>Poland G.A., Tosh P., Jacobson R.M. Requiring influenza vaccination for health care workers: Seven truths we must accept. Vaccine. 2005;23:2251–2255. doi: 10.1016/j.vaccine.2005.01.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.01.043</ArticleId><ArticleId IdType="pubmed">15755605</ArticleId></ArticleIdList></Reference><Reference><Citation>Simnani F.Z., Singh D., Kaur R. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: A review. 3 Biotech. 2022;12:15. doi: 10.1007/s13205-021-03076-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-021-03076-0</ArticleId><ArticleId IdType="pmc">PMC8665991</ArticleId><ArticleId IdType="pubmed">34926119</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W., Sia S.F., Schmitz A.J., Bricker T.L., Starr T.N., Greaney A.J., Turner J.S., Mohammed B.M., Liu Z., Choy K.T., et al. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. mBio. 2021;12:e0239521. doi: 10.1128/mBio.02395-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02395-21</ArticleId><ArticleId IdType="pmc">PMC8546861</ArticleId><ArticleId IdType="pubmed">34517754</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidarzadeh A., Amini Moridani M., Khoshmanesh S., Kazemi S., Hajiaghabozorgi M., Karami M. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: A test-negative case-control study. Int. J. Infect. Dis. 2023;128:212–222. doi: 10.1016/j.ijid.2022.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.12.024</ArticleId><ArticleId IdType="pmc">PMC9788848</ArticleId><ArticleId IdType="pubmed">36572376</ArticleId></ArticleIdList></Reference><Reference><Citation>Souan L., Abdel-Razeq H., Nashwan S., Al Badr S., Alrabi K., Sughayer M.A. COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation-A Single-Center Study. Vaccines. 2023;11:1659. doi: 10.3390/vaccines11111659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111659</ArticleId><ArticleId IdType="pmc">PMC10674399</ArticleId><ArticleId IdType="pubmed">38005991</ArticleId></ArticleIdList></Reference><Reference><Citation>Sughayer M.A., Souan L., Abu Alhowr M.M., Al Rimawi D., Siag M., Albadr S., Owdeh M., Al Atrash T. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies. Vaccine. 2022;40:2841–2847. doi: 10.1016/j.vaccine.2022.03.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.069</ArticleId><ArticleId IdType="pmc">PMC8971065</ArticleId><ArticleId IdType="pubmed">35397946</ArticleId></ArticleIdList></Reference><Reference><Citation>Malipiero G., D’Agaro P., Segat L., Moratto A., Villalta D. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Clin. Chim. Acta. 2022;524:11–17. doi: 10.1016/j.cca.2021.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.11.023</ArticleId><ArticleId IdType="pmc">PMC8630423</ArticleId><ArticleId IdType="pubmed">34843705</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Su J., Ma Y., Zhang W., Tang S. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Front. Immunol. 2022;13:945930. doi: 10.3389/fimmu.2022.945930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.945930</ArticleId><ArticleId IdType="pmc">PMC9459021</ArticleId><ArticleId IdType="pubmed">36090988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenart K., Arcoverde Cerveira R., Hellgren F., Ols S., Sheward D.J., Kim C., Cagigi A., Gagne M., Davis B., Germosen D., et al. Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2. NPJ Vaccines. 2024;9:17. doi: 10.1038/s41541-024-00806-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00806-2</ArticleId><ArticleId IdType="pmc">PMC10799869</ArticleId><ArticleId IdType="pubmed">38245545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenart K., Hellgren F., Ols S., Yan X., Cagigi A., Cerveira R.A., Winge I., Hanczak J., Mueller S.O., Jasny E., et al. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Mol. Ther. Methods Clin. Dev. 2022;27:309–323. doi: 10.1016/j.omtm.2022.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2022.10.001</ArticleId><ArticleId IdType="pmc">PMC9535876</ArticleId><ArticleId IdType="pubmed">36217434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y., Shang J., Sun S., Tai W., Chen J., Geng Q., He L., Chen Y., Wu J., Shi Z., et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol. 2020;94 doi: 10.1128/JVI.02015-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02015-19</ArticleId><ArticleId IdType="pmc">PMC7022351</ArticleId><ArticleId IdType="pubmed">31826992</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dodd K. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276. doi: 10.1016/S0140-6736(21)02717-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02717-3</ArticleId><ArticleId IdType="pmc">PMC8639161</ArticleId><ArticleId IdType="pubmed">34863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi A., Koch M., Wu K., Chu L., Ma L., Hill A., Nunna N., Huang W., Oestreicher J., Colpitts T. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: An interim analysis. Nat. Med. 2021;27:2025–2031. doi: 10.1038/s41591-021-01527-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01527-y</ArticleId><ArticleId IdType="pmc">PMC8604720</ArticleId><ArticleId IdType="pubmed">34526698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuenkitmongkol S., Solante R., Burhan E., Chariyalertsak S., Chiu N.-C., Do-Van D., Husin M., Hwang K.-P., Kiertiburanakul S., Kulkarni P.S. Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert. Rev. Vaccines. 2022;21:1255–1268. doi: 10.1080/14760584.2022.2092472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2092472</ArticleId><ArticleId IdType="pubmed">35748494</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitak-Arnnop P., Ngamskulrungroj P., Mahanonda N., Auychai P., Frech B., Shavlokhova V., Stoll C. Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review. Medicina. 2024;60:385. doi: 10.3390/medicina60030385.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina60030385</ArticleId><ArticleId IdType="pmc">PMC10971846</ArticleId><ArticleId IdType="pubmed">38541111</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P.D., Patil D.Y., Sahay R.R., Shete A.M., Mohandas S., Nair V. The impact of Omicron on the COVID-19 vaccines: A review. Vacunas. 2024;25:274–284. doi: 10.1016/j.vacun.2024.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vacun.2024.02.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott . ARCHITECT SARS-CoV-2 IgG II Reagent Instructions for Use. Abbott; Chicago, IL, USA: 2021. REF: 6R86-20.</Citation></Reference><Reference><Citation>Qiagen . QuantiFERON® SARSCoV-2 Starter Set Blood Collection Tubes Instructions for Use (Handbook) Qiagen; Germantown, MD, USA: 2021. REF: 626715.</Citation></Reference><Reference><Citation>QuantiFERON S. CoV-2 Extended Set Blood Collection Tubes Instructions for Use (Handbook)—QIAGEN. Qiagen; Germantown, MD, USA: 2021. REF: 626115.</Citation></Reference><Reference><Citation>Souan L., Sughayer M.A., Abualhour M.M., Siag M., Al-Badr S., Al-Atrash T. Comparison of the immunogenicity and protective efficacy of various SARS-CoV-2 vaccines among healthcare workers: Are our white coat armies protected? Vaccines. 2022;10:642. doi: 10.3390/vaccines10050642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050642</ArticleId><ArticleId IdType="pmc">PMC9143190</ArticleId><ArticleId IdType="pubmed">35632398</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcotte H., Piralla A., Zuo F., Du L., Cassaniti I., Wan H., Kumagai-Braesh M., Andréll J., Percivalle E., Sammartino J.C., et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022;25:103743. doi: 10.1016/j.isci.2022.103743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103743</ArticleId><ArticleId IdType="pmc">PMC8736281</ArticleId><ArticleId IdType="pubmed">35018336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakare A.A., Sogbesan A., Herzig Van Wees S.A., Salako J.A., Bakare D., Olojede O.E., Akinsola K., Bakare O.R., Falade A.G., King C. Exploring COVID-19 Pandemic Perceptions and Vaccine Uptake among Community Members and Primary Healthcare Workers in Nigeria: A Mixed Methods Study. medRxiv. 2024</Citation></Reference><Reference><Citation>Coleman B.L., Gutmanis I., Bondy S.J., Harrison R., Langley J., Fischer K., Cooper C., Valiquette L., Muller M.P., Powis J. Canadian health care providers’ and education workers’ hesitance to receive original and bivalent COVID-19 vaccines. Vaccine. 2024;42:126271. doi: 10.1016/j.vaccine.2024.126271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.126271</ArticleId><ArticleId IdType="pubmed">39226785</ArticleId></ArticleIdList></Reference><Reference><Citation>Buoninfante A., Andeweg A., Genov G., Cavaleri M. Myocarditis associated with COVID-19 vaccination. NPJ Vaccines. 2024;9:122. doi: 10.1038/s41541-024-00893-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00893-1</ArticleId><ArticleId IdType="pmc">PMC11213864</ArticleId><ArticleId IdType="pubmed">38942751</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallatah N.I., Alrehaili B.O., Alsulami S.S., Al-Zalabani A.H. Menstrual Changes Following COVID-19 Vaccination: A Cross-Sectional Study. Medicina. 2024;60:206. doi: 10.3390/medicina60020206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina60020206</ArticleId><ArticleId IdType="pmc">PMC10890281</ArticleId><ArticleId IdType="pubmed">38399494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A.A., Ying N.Y. Hesitancy to COVID-19 Vaccine Among Healthcare Workers: A Scoping Review. Borneo J. Med. Sci. (BJMS) 2024;18:148–172.</Citation></Reference><Reference><Citation>Neuhann J.M., Stemler J., Carcas A.J., Frías-Iniesta J., Akova M., Bethe U., Heringer S., Salmanton-García J., Tischmann L., Zarrouk M., et al. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1) Vaccine. 2023;41:7166–7175. doi: 10.1016/j.vaccine.2023.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.10.029</ArticleId><ArticleId IdType="pubmed">37919141</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan N.H., Sablerolles R.S.G., Rietdijk W.J.R., Goorhuis A., Postma D.F., Visser L.G., Bogers S., Geers D., Zaeck L.M., Koopmans M.P.G., et al. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol. Front. Immunol. 2022;13:1067749. doi: 10.3389/fimmu.2022.1067749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1067749</ArticleId><ArticleId IdType="pmc">PMC9744953</ArticleId><ArticleId IdType="pubmed">36524126</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Leeuwen L.P.M., Grobben M., GeurtsvanKessel C.H., Ellerbroek P.M., de Bree G.J., Potjewijd J., Rutgers A., Jolink H., van de Veerdonk F.L., van Gils M.J., et al. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. Front. Immunol. 2024;15:1390022. doi: 10.3389/fimmu.2024.1390022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1390022</ArticleId><ArticleId IdType="pmc">PMC11063285</ArticleId><ArticleId IdType="pubmed">38698851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hönning A., Tomczyk S., Hermes J., Grossegesse M., Hofmann N., Michel J., Neumann M., Nitsche A., Hoppe B., Eckmanns T., et al. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination. BMC Infect. Dis. 2024;24:436. doi: 10.1186/s12879-024-09338-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09338-5</ArticleId><ArticleId IdType="pmc">PMC11040945</ArticleId><ArticleId IdType="pubmed">38658874</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiménez M., Fernández-Naval C., Navarro V., Novoa S., Martinez-Gallo M., Medina D., Andrés C., Antón A., Peralta S., Pujadas G., et al. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. Am. J. Hematol. 2023;98:1204–1213. doi: 10.1002/ajh.26951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26951</ArticleId><ArticleId IdType="pubmed">37151135</ArticleId></ArticleIdList></Reference><Reference><Citation>Primorac D., Brlek P., Matišić V., Molnar V., Vrdoljak K., Zadro R., Parčina M. Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. Vaccines. 2022;10:442. doi: 10.3390/vaccines10030442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030442</ArticleId><ArticleId IdType="pmc">PMC8953558</ArticleId><ArticleId IdType="pubmed">35335076</ArticleId></ArticleIdList></Reference><Reference><Citation>Almendro-Vázquez P., Laguna-Goya R., Ruiz-Ruigomez M., Utrero-Rico A., Lalueza A., Maestro de la Calle G., Delgado P., Perez-Ordoño L., Muro E., Vila J., et al. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. PLoS Pathog. 2021;17:e1010211. doi: 10.1371/journal.ppat.1010211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010211</ArticleId><ArticleId IdType="pmc">PMC8757952</ArticleId><ArticleId IdType="pubmed">34962970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H., Jyssum I., Alirezaylavasani A., Egner I.M., Tietze L., Lund K.P., Tveter A.T., Provan S.A., Ørbo H., Haavardsholm E.A. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: A prospective cohort study. Front. Immunol. 2024;15:1296273. doi: 10.3389/fimmu.2024.1296273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1296273</ArticleId><ArticleId IdType="pmc">PMC10917913</ArticleId><ArticleId IdType="pubmed">38455062</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton W., Oriol G., Compagnon C., Saade C., Saker K., Franc P., Mokdad B., Fleurie A., Lacoux X., Daniel S. Combining SARS-CoV-2 interferon-gamma release assay with humoral response assessment to define immune memory profiles. Eur. J. Immunol. 2024;54:2451035. doi: 10.1002/eji.202451035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202451035</ArticleId><ArticleId IdType="pubmed">38627984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray-Gaillard S.L., Solis S.M., Chen H.M., Monteiro C., Ciabattoni G., Samanovic M.I., Cornelius A.R., Williams T., Geesey E., Rodriguez M., et al. SARS-CoV-2 inflammation durably imprints memory CD4 T cells. Sci. Immunol. 2024;9:eadj8526. doi: 10.1126/sciimmunol.adj8526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.adj8526</ArticleId><ArticleId IdType="pubmed">38905326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Yang X., Mei X., Zhou Y., Tang Z., Li G., Zhong J., Yu M., Huang M., Su X., et al. SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies. Signal Transduct. Target. Ther. 2022;7:132. doi: 10.1038/s41392-022-00978-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00978-0</ArticleId><ArticleId IdType="pmc">PMC9034077</ArticleId><ArticleId IdType="pubmed">35461307</ArticleId></ArticleIdList></Reference><Reference><Citation>Cañete P.F., Vinuesa C.G. COVID-19 Makes B Cells Forget, but T Cells Remember. Cell. 2020;183:13–15. doi: 10.1016/j.cell.2020.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.013</ArticleId><ArticleId IdType="pmc">PMC7472965</ArticleId><ArticleId IdType="pubmed">32976799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N., Collier A.-R.Y., Miller J., Hachmann N.P., Liu J., Anand T., Bondzie E.A., Fisher J.L., Mazurek C.R., Patio R.C. Waning immunity and IgG4 responses following bivalent mRNA boosting. Sci. Adv. 2024;10:eadj9945. doi: 10.1126/sciadv.adj9945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adj9945</ArticleId><ArticleId IdType="pmc">PMC10889350</ArticleId><ArticleId IdType="pubmed">38394195</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade C., Bruel T., Vrignaud L.-L., Killian M., Drouillard A., Barateau V., Espi M., Mariano N., Mignon C., Bruyère L. Impact of SARS-CoV-2 Vaccine and Infection History on Antiviral Immunity Post Breakthrough Infection.  [(accessed on 5 August 2024)].  Available online:  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4830491.</Citation></Reference><Reference><Citation>Akhtar M., Islam M.R., Khaton F., Soltana U.H., Jafrin S.A., Rahman S.I.A., Tauheed I., Ahmed T., Khan I.I., Akter A. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Front. Immunol. 2023;14:1309997. doi: 10.3389/fimmu.2023.1309997.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1309997</ArticleId><ArticleId IdType="pmc">PMC10763240</ArticleId><ArticleId IdType="pubmed">38173725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>